What is the MRI SWAN (Susceptibility Weighted Angiography) sequence and when should it be used?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

MRI SWAN Sequence

SWAN (Susceptibility Weighted Angiography) is a 3D gradient-echo MRI sequence manufactured by GE that detects blood products, iron deposits, calcifications, and vascular structures by exploiting magnetic susceptibility differences between tissues—it is essential for identifying small cavernous malformations, microbleeds, and venous abnormalities that conventional T2 sequences miss.* 1

What SWAN Is

SWAN is GE's proprietary version of susceptibility-weighted imaging, equivalent to Siemens' SWI and Philips' VenoBOLD 1, 2. It uses a 3D spoiled gradient-echo sequence with multiple echo acquisitions and appropriate echo times to maximize visualization of susceptibility differences between adjacent tissues 2, 3. The sequence provides high spatial resolution with significantly shorter acquisition times compared to older techniques 3, 4.

Key Clinical Applications

Cavernous Malformations (Primary Indication)

SWAN is mandatory for evaluating cavernous malformations because it detects small lesions that traditional T2 gradient-echo sequences cannot visualize.* 1 According to 2026 consensus guidelines:

  • SWAN must be included in standard MRI protocols for suspected or known cavernous malformations 1
  • It identifies both the classic "popcorn" appearance with hemosiderin rings and tiny hemorrhagic foci 1
  • Critical for establishing baseline lesion burden in familial cavernous malformation patients 1
  • Superior sensitivity for detecting new lesions on follow-up imaging 1
  • At least 1.5T MRI is required; 3T or stronger detects more small lesions 1

Cerebral Microbleeds and Hemorrhage Detection

SWAN demonstrates superior sensitivity for:

  • Microbleeds in aging, dementia, and mild traumatic brain injury 5
  • Superficial siderosis in Alzheimer disease and amyloid angiopathy 5
  • Hemorrhagic transformation of arterial infarcts 6
  • Hypertensive microhemorrhages 6

In CAA-related inflammation, SWAN (or equivalent susceptibility sequences) is strongly recommended as part of the diagnostic workup to identify lobar microbleeds and cortical superficial siderosis. 7

Vascular Malformations

  • Developmental venous anomalies (DVAs): SWAN identifies these without contrast, appearing as hypointense venous structures 8, 9
  • High-flow vascular malformations: Draining veins appear hyperintense (bright) on SWAN due to high-velocity arterial flow—this distinguishes arteriovenous malformations from slow-flow lesions 8, 10
  • Venous angiomas: SWAN detects symptomatic venous angiomas causing focal seizures with high accuracy 9
  • Cerebral veins and arteries: MinIP reconstructions excel for venous visualization; MIP reconstructions show arterial structures 4

Stroke Imaging

SWAN provides critical supplemental information in acute stroke:

  • Detects intraarterial thrombus 6
  • Identifies hemorrhagic venous infarcts in cerebral venous sinus thrombosis 6
  • Reveals asymmetrically prominent cortical veins indicating venous congestion 5
  • Shows concomitant microbleeds affecting therapeutic decisions (e.g., thrombolysis eligibility) 6

However, T2 remains superior to SWAN for acute venous thrombosis detection, particularly near the skull base* 11—this is SWAN's main weakness.

Other Applications

  • Iron deposition in neurodegenerative diseases (Parkinson disease, dementia with Lewy bodies) 5
  • Central vein sign in multiple sclerosis 5
  • Intratumoral susceptibility signals differentiating tumor types 5
  • Infectious aneurysms (appear bright due to high-flow) 10

Technical Advantages

  • Acquisition time: 3-4 minutes, significantly shorter than phase-sensitive imaging while achieving equivalent susceptibility weighting 3, 6
  • No contrast required: Visualizes both veins and arteries without gadolinium 4
  • Multiple reconstructions: Source images, 2D reformats, MinIP (for veins), and MIP (for arteries) from single acquisition 4

Critical Pitfalls

  1. Skull base limitations: SWAN performs worse than T2* for detecting acute venous thrombosis in sigmoid sinuses and intracranial internal jugular veins due to susceptibility artifacts 11

  2. Not a substitute for DSA: While useful for screening and follow-up, digital subtraction angiography remains gold standard for high-flow vascular malformations requiring intervention 8

  3. Interpretation requires experience: Distinguishing true pathology from artifacts, particularly near air-tissue interfaces, demands expertise 2

  4. Field strength matters: 3T detects more lesions than 1.5T, but also generates more artifacts 1

Recommended Protocol Integration

Based on 2026 guidelines for cavernous malformations (applicable broadly) 1:

  1. T1-weighted without contrast
  2. T2-weighted
  3. SWAN (or equivalent susceptibility sequence)
  4. FLAIR (for edema)
  5. Diffusion-weighted imaging
  6. Contrast-enhanced T1 only if evaluating for tumor or detailed vascular anatomy

SWAN should be standard in stroke protocols, seizure workups, suspected vascular malformations, and neurodegenerative disease evaluations—the additional 3-4 minutes provides diagnostic information that directly impacts management decisions. 6

References

3
Research

Clinical value of 3D T₂*-weighted imaging with multi-echo acquisition: comparison with conventional 2D T₂*-weighted imaging and 3D phase-sensitive MR imaging.

Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine, 2012

Related Questions

What is the clinical significance of blooming on Susceptibility Weighted Imaging (SWI) MRI images, particularly in adults with a history of stroke or trauma?
How does Ritalin (methylphenidate) compare to Adderall (mixed amphetamine salts) in terms of potency, duration of action, and typical dosing?
In a 43-year-old male with acute rhabdomyolysis, are the markedly elevated creatine kinase (CK), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) all attributable to the rhabdomyolysis?
What dose and duration of Garcinia cambogia (hydroxy‑citric acid) use are associated with hepatotoxicity?
Can non‑alcoholic chronic liver disease present with a high‑sensitivity C‑reactive protein (hsCRP) level of 70 mg/L?
In an elderly adult being evaluated for cognitive decline, seizures, or focal neurological deficits, when should a Phase‑Sensitive Inversion‑Recovery (PSIR) sequence be added to the brain MRI protocol, and what are the recommended imaging parameters?
What is the Phase‑Sensitive Inversion‑Recovery (PSIR) MRI sequence and what are its clinical uses?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.